Adani Energy Raises Big
- 02nd Jun 2025
Aaj Ka Bazaar
Wall Street wrapped up a mixed session on Friday after experiencing heightened volatility, rebounding from session lows after President Donald Trump indicated that he planned to speak with Xi Jinping following accusations that China had breached a trade agreement. The S&P 500 ended virtually unchanged, slipping just 0.01 percent. The Nasdaq fell 0.32 percent, while the Dow Jones rose 0.13 percent. Asia-Pacific markets opened mixed after U.S. President Donald Trump announced a sharp increase in tariffs on steel imports. Gift Nifty was trading lower, indicating a marginally negative start to the day in the Indian market. As the day progresses, investors will react to stronger-than-expected Q4 GDP data, along with the final U.S. and India manufacturing PMI figures for May. This upbeat data, combined with favorable macroeconomic indicators such as an early monsoon onset and a benign inflation outlook, is expected to support market momentum despite prevailing global uncertainties. In stock-specific news, IOC will remain in focus today as the company has finalised the levelized cost of hydrogen for setting up a 10,000 tonnes per annum green hydrogen generation unit at its Panipat refinery and petrochemical complex. This marks the company’s entry into the green hydrogen space with India’s largest-ever green hydrogen project to date.
Markets Around Us
BSE Sensex – 80,879.25 (-0.16%)
Nifty 50 – 24,579.85 (-0.71%)
Bank Nifty – 55,527.75 (-0.38%)
Dow Jones – 42,120.99 (-0.36%)
Nasdaq – 19,175.87 (0.39%)
FTSE – 8,772.38 (0.64%)
Nikkei 225 – 37,437.69 (-1.39%)
Hang Seng – 22,778.45 (-2.24%)
Sector: Power
Adani Energy to Raise Funds via Stake
Adani Energy has decided to raise $502 million by selling shares through a method called Qualified Institutional Placement (QIP), which allows companies to sell shares to big investors like banks or mutual funds. This move is part of the Adani Group’s broader effort to strengthen its finances and win back investor trust after facing challenges earlier, including legal issues in the US. In recent months, the group has been actively securing funds $750 million in April for an acquisition, with support from major investors like BlackRock, and $150 million last week through a loan from DBS Bank. Credit rating agency Fitch recently improved its outlook on Adani Energy, saying the group has shown it still has good access to funding. This fundraising is expected to help the company manage its debt, invest in new projects, and signal to the market that it remains financially stable and growth-focused.
Why it Matters:
This fundraise signals growing investor confidence in Adani Group after recent controversies. It strengthens Adani Energy’s financial position, helping it invest in future projects and manage debt. For traders, it indicates renewed momentum and stability in a key energy stock.
NIFTY 50 GAINERS
APOLLOHOSP – 7065.00 (2.68%)
ADANIPORTS– 1455.60 (1.59%)
COALINDIA – 400.60 (0.83)
NIFTY 50 LOSERS
HEROMOTOCO – 4221.30 (-2.04%)
BAJAJ-AUTO – 8451.50 (-1.81%)
JSWSTEEL – 976.80 (-1.68)
Sector : Pharmaceuticals
Alembic Pharmaceuticals has received final approval from the USFDA to sell its generic version of Bosutinib tablets in the U.S. market. This drug is used to treat adults with a specific type of blood cancer called chronic myelogenous leukemia (CML), especially those who didn’t respond well to earlier treatments. Alembic’s version is equivalent to Pfizer’s brand-name drug Bosulif, meaning it works the same way and offers the same benefits at likely a lower cost. The market for Bosutinib tablets in the U.S. is estimated to be around $291 million as of March 2025, offering Alembic a strong revenue opportunity. This approval adds to Alembic’s growing presence in the U.S. generic drug market, where it now holds 223 ANDA approvals in total. As a vertically integrated company, Alembic handles everything from R&D to production, helping ensure quality and cost efficiency. This move boosts its credibility and growth prospects in oncology.
Why it Matters:
This approval allows Alembic to enter a $291 million cancer drug market in the U.S. It strengthens the company’s oncology portfolio and boosts its U.S. generics presence. For investors, it signals steady growth and revenue potential.
Around the World
Asian stock markets fell on Monday due to rising concerns over a potential U.S.-China trade war after President Trump accused China of breaking a recent trade deal, which China strongly denied. Investors were also worried after Trump raised tariffs on steel and aluminum imports, creating uncertainty about U.S. trade policy. Tensions between Russia and Ukraine and possible new U.S. tariffs on China and India for buying Russian oil added to the negative sentiment. Weak Chinese economic data and ongoing trade tensions further hurt investor confidence, especially in Hong Kong, where the Hang Seng index dropped 2.3%. Japan’s Nikkei fell 1.5%, while other markets like Australia, Singapore, and India also saw mild declines. However, India’s strong GDP growth may help limit further losses. South Korea’s market was an exception, gaining slightly ahead of its presidential elections. Overall, traders are cautious due to geopolitical tensions, weak Chinese data, and uncertain global trade outlook.
Option Traders Corner
Max Pain
Nifty 50 – 24700
Bank Nifty – 55000
Nifty 50 – 24777 (Pivot)
Support – 24,690, 24,630, 24,544
Resistance – 24,837, 24,923, 24,983
Bank Nifty – 55639 (Pivot)
Support – 55,466, 55,183, 55,009
Resistance – 55,923, 55,096, 56,379
Have you checked our latest YouTube Video
Did you know?
Printing Money Just Got Costlier
Did you know the RBI will spend ₹6,372.8 crore on security printing in 2024-25? That’s a 25% jump from last year’s ₹5,101.4 crore all driven by the rising demand for banknotes. Yes, even printing money comes with a heavy price tag!
